Skip to main content
. 2008 Nov 18;99(12):2020–2028. doi: 10.1038/sj.bjc.6604783

Figure 5.

Figure 5

Effects of CI-1040 on cell proliferation. Cells were counted after 72 h of CI-1040 or DMSO (control) treatment. The mutational status of KRAS and BRAF for each sample is shown under the cell lines and primary cancer cell cultures. Ovarian cancers with mutations in either KRAS or BRAF are more sensitive to growth inhibition by CI-1040 than those with wild-type (WT) sequences.